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Abstract
CHOLINE INHIBITION OF PROTHROMBINASE
by
Richard D. Leach
The purpose of this study was to characterize the inhibitory effects of
choline on the terminal enzymatic complex of the blood coagulation cascade. 
Reports in the literature have indicated that choline lengthens whole plasma
clotting time with a likely site of inhibition being the step that converts
prothrombin (II) to thrombin (Ha).
ii
In order to quantitate the effects of choline on prothrombinase activity,
bovine factor V and human factor II were isolated in this laboratory by
established methods, and other prothrombinase components were obtained from
The activity of venom-activated bovine factor Xa wascommercial sources.
assayed in the presence of factors II and Va, phospholipid, Caz+, and
chromogenic substrate (Kabi S-2238). The release of p-nitroaniline from S-2238 
was measured, by continuous spectrophotometric monitoring of incubation
mixtures at 400 nm, as an index of Ha production.
Under these assay conditions, choline acted as a mixed-type inhibitor of 
the prothrombinase complex with an apparent Kj of 25 mM and an apparent Kj' 
At similar concentrations, choline also increased the activatedof 41 mM.
coagulation time of whole-blood. The inhibition of prothrombinase activity was 
independent of [Caz+], factor Va, and micelle phospholipid composition, 
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Prothrombinase, the terminal enzymatic complex of the blood coagulation
cascade, is composed of two proteins—factors Xa and Va, negatively charged 
phospholipid (or platelets), and Ca . This complex catalyzes the conversion of 
prothrombin to thrombin. The two prothrombinase proteins, although present as
precursors in trace amounts in plasma, are present in greater abundance than
the other coagulation proteins earlier in the cascade. Because these component 
proteins are available in sufficiently large quantity, prothrombinase is currently
the most studied and best understood of the complex enzymes of the
coagulation cascade (1, 2). Previous studies have shown that (a) a mixture of at
least two phospholipids (particularly phosphatidylserine with either 
phosphatidylcholine or phosphatidylethanolamine) produces the highest 
prothrombinase activity (2), and (b) maximal activity also requires a net
negative surface charge, which is facilitated by factor Va. This factor allows
lateral phase separation (clustering) of acidic phospholipids in membranes (3).
Although inhibition of prothrombinase activity is of interest, not only to 
enzymologists, but also to physicians, because of the clinical need for
regulation of coagulation, relatively little is known about the significance of
naturally occuring prothrombinase inhibitors. Nath and Vaishwanar (4) first
reported that incubation of choline with human plasma at 37°C results in an
inhibition of blood clotting. Norrid and Cooper (3) obtained data indicating that
choline inhibits the conversion of prothrombin to thrombin, but the mechanism
was not determined.
The present study utilizes purified prothrombinase components to focus
on specific effects of choline on blood clotting. In this study we present
1
2
kinetic data showing that choline acts as a mixed-type inhibitor of
prothrombinase. We also report apparent inhibition constants (KT and Kr1). This




A thrombin-specific chromogenic substrate, S-2238, was purchased from
Kabi Diagnostica. Factor V-deficient plasma was from Dade Diagnostics. 
Choline chloride and polyethyleneglycol (PEG) 20,000 were obtained from
Sigma. Sodium barbital was from Biochemical Laboratories. All reagents were
of the highest grade commercially available.
Proteins
Bovine factor Xa, which had been activated by Russell's Viper Venom
(RVV), was purchased from Sigma. Human factor II was isolated as a by-product 
of the purification of factor IX according to the methods of Di Scipio (6) and
Miletich (7). Bovine factor V was isolated and its activity measured by its
ability to correct the prolonged prothrombin time of factor V-deficient plasma
as described by Nesheim (8). Factor Xa was stored in 0.04 M sodium citrate (pH
5.8) and PEG (4 mg/ml). Factor II was stored in 0.05 M imidazole-HCl, 2.5 mM
CaCl 1.0 M NaCl (pH 6.0). Factor V was stored in 0.01 M Tris-borate, 1.0 
mM CaC^, 50% glycerol (pH 8.3). All of the above protein solutions were 




Concentrations of factor Xa ranged between 3.5 and 5.5 x 10-Zf units/ml. 
The concentration of factor V was estimated, following pre-activation with 
thrombin, by a factor Va clotting assay. The factor V concentration ranged 
from 0.7 to 1.1x10“^ units/ml. The factor II concentration, as determined by a
factor II-deficient plasma clotting assay with RVV as the activator, ranged 
between 0.01 and 0.75 units/ml.
Phospholipid and Phospholipid Vesicle Preparations
Phosphatidylserine (bovine brain extract, PS) was obtained from Sigma.
L-alpha-phosphatidylcholine (egg-yolk extract, PC) was purchased from 
Calbiochem-Behring. 
chloroform-methanol solvent, were mixed on a w/w basis in glass tubes and 
dried under an Ar stream. In an ice bath, vesicles of phospholipid (1 mg/ml)
The phospholipids (POPS, 3:1), dissolved in a
were prepared by sonication with added buffer containing 7.15 mM Na barbital 
(pH 7.35). Sonication (Heat Systems Micro-Tip ultrasonicator) was effected by a
microprobe for nine minutes at a setting of 3.5 output and 50% duty cycle.
Phospholipid vesicles were prepared fresh weekly. No more than two kinetic
experiments were performed with each phospholipid preparation. Variability of
activity from one experiment to another seemed to be a technical difficulty
attributable to phospholipid vesicle deterioration and differences from one
preparation to another.
Measurement of Rates of Thrombin Production
An enzyme mixture consisting of factors Xa and Va, 2.5 mM CaCl 
PEG (1 mg/ml) was prepared in plastic cuvettes (1 cm light path) and kept on
and2’
4
ice. Ten minutes later, veronal buffer (7.15 mM sodium barbital) at pH 7.35,
NaCl, PEG (1 mg/ml), and phospholipid (1 mg/ml) were added. Sonication in a
vacuum chamber removed air bubbles that otherwise formed on cuvette walls
and interfered with spectrophotometric readings during the assay. This mixture
was subsequently pre-incubated for 20 min at 37°C. (When choline was used it
was added to the above factor Xa-Va mixture just prior to the veronal buffer
addition.) Simultaneously, a substrate mixture containing factor II, PEG (1 
mg/ml), 2.5 mM CaC^, NaCl, 7.15 mM sodium barbital (pH 7.35), and 0.1 mM 
S-2238 was pre-incubated for 10 min at 37°C. This pre-incubation was timed to 
end simultaneously with the 20 min pre-incubation of the enzyme mixture
(Xa-Va). Thrombin production was initiated when the substrate mixture was
added to the enzyme mixture. Production of thrombin was measured during the 
12 min incubation that ensued at 37°C by continuous, sequential
spectrophotometric monitoring (Gilford) of four incubation mixtures
representing duplicates of two reaction conditions. The average absorbance of
each cuvette was recorded for 7 sec of a 28 sec cycle at 400 nm as
p-nitroaniline (PNA) was released from the chromogenic substrate, S-2238. The
spectrophotometer was interfaced with a computer (Cromemco) to record the
(The NaCl in the above mixtures was from a 1 M stock solution.absorbance.
Appropriate volumes were used to make a final ionic strength of 310 meq/1 in
the cuvettes.)
According to Kosow (9), who measured the rate of plasmin formation
with a similar assay, the rate of formation of thrombin is proportional to the
acceleration of the rate of hydrolysis of S-2238. The equation describing this
2
=VQt+l/2at where t is sec, a is acceleration, and Vq is the 
spontaneous non-enzymatic rate of hydrolysis of S-2238. This equation is valid
relationship is A 400
5
only when thrombin production is linear (i.e. when saturating concentrations of
factor II and S-2238 are present). Therefore, the reaction is followed for a 
short time prior to significant decreases in the amounts of either prothrombin 
or S-2238, and as a result, both Vq and a are constant. Since the acceleration 
is constant, a graphic analysis of A^QQ-vgt vs t produces a straight line with 
a slope of a/2. This slope is proportional to the rate of formation of thrombin.
For S-2238 under the conditions used in this study, Vq Was undetectable, 
so the ordinates of plots were labelled A^qq instead of A^QQ-v0t. 
computer collected the absorbance readings with time and fitted these data by
The
linear regression to the above equation. The computer also calculated the slope 
(a/2) of the line and determined the correlation coefficients which averaged
0.996 + 0.006 (x + SD, n=307).
Kinetic Analysis
Michaelis-Menten kinetics were applied to analyze our data for
prothrombin activation. Since the rates of thrombin formation in the presence
of different concentrations of substrate (II) with or without inhibitor (choline)
were proportional to the slope a/2, we used that value as an index of velocity
for the reaction. The reciprocal of the velocity of thrombin formation
(normalized for variations in factor Xa concentration and phospholipid
preparation) was plotted versus reciprocal factor II concentration. These
Lineweaver-Burk (LB) plots were linear over a wide range of prothrombin
The correlation coefficients averaged 0.97 _+ 0.02 (3? +_ SD, 
n=36). The slopes and intercepts from the LB plots were then replotted versus
concentrations.
choline concentration to yield apparent values for the inhibition constants K I
and K The initial velocity data were also plotted in the form of a Dixon plotI *
6
(1/velocity versus inhibitor concentration).
RESULTS
Optimization of Assay Conditions
Reaction conditions, prothrombin concentration range, and composition of
activating mixtures were determined in preliminary kinetic experiments. An
attempt was made to utilize an assay system similar to physiological conditions. 
Total ionic strength was maintained at 310 meq/1, which is near normal human
plasma ionic strength (10, 11). According to Rosing et. al. (12) and Lindhout et. 
al. (13), the rate of prothrombin activation increases to an optimum when the
2+ 2 +concentration is increased from 0 to 3 mM. At higher CaCa
concentrations the rate of prothrombin activation decreases. We used 2.5 mM
2 + , which is in the mid-range of normal human plasma concentration and alsoCa
near the optimum concentration reported for jn vitro prothrombin activation
(12, 13). Physiological concentrations of factors Xa and Va caused the
prothrombin activation to proceed so rapidly that the kinetics could not be
observed with our instrumentation. Therefore, the enzymatic components were
present at levels which optimized the rate in the presence of the complete
prothrombinase complex. The reaction rate remained linear over the 12 min
assay period, even at the lowest and highest prothrombin concentrations
studied.
Inhibition of Whole Blood Coagulation by Choline
The activated coagulation time (ACT) (14) of normal whole blood was
7
116 +_ 10 sec (x _+ SD, n=4). Addition of choline to a final concentration of 30
mM increased the ACT by 16.5% to 134 _+ 13 sec (x +_ SD, n=2). Addition of 45 
mM choline increased the ACT by 23% to 142 _+ 12 sec (x _+ SD, n=3).
Inhibition of Prothrombin Activation by Choline
We studied the inhibition of prothrombin activation by choline in nine 
experiments using inhibitor concentrations of 15 mM, 30 mM, and 45 mM.
Choline, although not an alternative substrate for factor Xa, decreased the 
maximum reaction rate while the KM(app) remained constant or increased,
Double-reciprocal analyses of our initial 
velocity data for choline inhibition of prothrombin activation demonstrated 
intersection in the second quadrant (Fig. 1), also consistent with a mixed-type 
Replots of slopes and y-intercepts as functions of inhibitor 
concentrations were linear (Figs. 2 and 3). The value of Kj(app), as determined 
from the abscissa intercept of the slope replot, was 25 ^ 4 mM (SE) choline. 
The value of Kj'(app) determined from the intercept replot was 41 ^ 4 mM (SE) 
choline. The value of Kj(app)
reflecting a mixed-type inhibition.
inhibition (15).
was consistently less than the value of Kj'(app) in 
all experiments; and the two values were always significantly different
(p<0.005) as determined by the paired t-test. Since Kj' was greater than Kj, 
the value of K^(app) should increase in the presence of inhibitor (15), and this 
was, in fact, observed. (K^=0.13 in the absence of inhibitor; Kjyj=0.26 in the 
presence of 30 mM choline.) The Dixon plot of the inhibition data (Fig. 4) was 
linear with an intersection at [I]=-KT in the second quadrant. The value of
Kj(app) calculated from this plot was 27 ^ 4 mM (SE) choline, in agreement 
with our previous analysis by double-reciprocal plot. Dixon plots for mixed-type
inhibition systems are usually curved. Linear Dixon plots (like Fig. 4) indicate
8
that the enzyme-substrate-inhibitor (ESI) complex is not catalytically active.
As shown in Table 1, the same type of mixed inhibition with similar 
apparent inhibition constants (Kp was noted in the absence of factor Va, at 
concentrations, and with different phospholipid compositions.2+various Ca
DISCUSSION
Our data clearly demonstrate that choline is a mixed-type inhibitor of
prothrombinase activity with respect to factor II. Since the inhibition occurred
2 + concentrations, andin the presence or absence of factor Va, at various Ca 
with different phospholipid compositions (Table 1), choline probably interacted
with either factor Xa or factor II or both. Alternatively, the inhibition may
2+ , phospholipid,have been a function of the interaction of the components Ca
factors Xa and II altogether with choline.
Nelsestuen (16) and van Rijn (17) have proposed that prothrombinase is a
dissociable three-component enzyme (factor Xa-factor Va-phospholipid) which
acts on soluble prothrombin. The most active form of prothrombinase consists
of a negatively charged phospholipid surface associated with factor Xa via
calcium bridges between gamma-carboxyglutamic acids of its light chain, while 
factor Va binds to the phospholipids by an hydrophobic and/or electrostatic
interaction. The affinity for prothrombin is the result of additive free energies
of prothrombin-factor Va and prothrombin-phospholipid interactions occurring
at the active site of prothrombinase. If this model is correct, choline could 
have interfered with these interactions by direct binding to a) the 
gamma-carboxyglutamic acid residues present on factor Xa and factor II or b)
9
the acidic (negatively charged) phospholipids. The binding of choline to factor
Xa could inhibit the reaction either by changing the conformation of the active 
site or by inhibiting factor Xa binding to the phospholipid surface and to 
factor Va. Although our data demonstrate that different micellar phospholipid
compositions did not differ with respect to choline inhibition, it is possible that
choline-phospholipid binding, in general, could inhibit the normal binding of 
factors Xa and II to the phospholipid via calcium bridging. Saturating
concentrations of factor II should be able to overcome choline inhibition, if it
is due solely to factor II-choline interactions.
Complete characterization of prothrombinase-choline interactions will,
however, require additional studies. Nuclear Magnetic Resonance (NMR) spectra 
of choline in the presence and absence of factors II, Va, and Xa should allow
identification of specific protein(s) interactions with choline and calculation of
the number of protein binding sites for choline. (Binding to a protein should 
alter the NMR spectrum of choline by changing that peak of the choline 
spectrum which is caused by the protons associated with the methyl groups of
the quaternary amine.) Substitution of other substances (e.g., ethanolamine) for 
choline should allow determination of whether the inhibition is specific for 
choline. A complete kinetic analysis of this complex system will require that
each component be systematically varied while all other component
concentrations are held constant.
Although we found that choline inhibits prothrombinase activity, the
inhibition constants we observed are two to three orders of magnitude greater 
than the normal plasma concentration of choline. Wurtman et al. (18) reports 
mM choline as normal, whereas Zeisel (19) reports that normal0.01
concentrations may be as high as 0.1 mM. Hawk's Physiological Chemistry (20)
10
reports blood concentrations of 0.005-0.24 mM. At such physiological levels,
choline is not likely to play an important role in controlling this step of
intrinsic blood coagulation. However, further studies are needed to determine 
serum-choline concentrations in humans and animals on varying choline intakes
via parenteral or enteral routes for prolonged periods of time.
In conclusion, the results of these studies demonstrate that choline is a
mixed-type inhibitor of the prothrombinase complex with an apparent K. of 25
mM and an apparent KT' of 41 mM. At similar concentrations, choline alsoI
The inhibition ofincreased the activated clotting time of whole-blood, 
prothrombinase activity was independent of [Ca/+], factor Va, and micelle






Table 1 Choline inhibition of prothrombinase activity: Dependence on reaction 
componentsa
Reaction components*3 Kjfepp)0Factor Va n
Standard 925 + 4 mM+
21+3 mM 8Standard
POPS (1:3, w/w) 27 +10 mM 5
2+ 18 + 2 mM 25.0 mM Ca
2+1.5 mM Ca 27 + 4 mM 3
Choline inhibition of prothrombinase activity was determined as a function 
of [factor II] at 0, 15, 30, and 45 mM choline, and the inhibition pattern was
a
determined from L-B analyses of initial velocity data. The inhibition was
mixed-type in all above cases.
The standard reaction mixture contained: Factor II (0.01-0.75 U/ml), factor 
Va (0.7-1.1 x 10~4 U/ml), factor Xa (3.5-5.5 x 10"^ U/ml), 1 mg/ml phospholipid 
(POPS, 3:1, w/w), 2.5 mM CaCl
b
1 mg/ml PEG 20,000, 7.15 mM sodium barbital 
(pH 7.35), 0.1 mM S-2238, and NaCl (1 M stock) to adjust final ionic strength to
2’
310 meq/1. For comparison, prothrombinase activity was also analyzed in the
absence of factor Va, with a different phosopholipid mixture, and with 5.0 mM
Ca^+ and 1.5 mM Ca2 + substituted for the standard 2.5 mM Ca .
Values of Kj(app) were calculated from replots of the slope of the L-B 




Fig. 1 The Lineweaver-Burk (L-B) plot (1/v vs 1/[S]) of choline inhibition 
of prothrombinase activity. Choline concentrations were 0 (O), 15
(□), 30 (A), and 45 (■) mM. Choline chloride was replaced by
NaCl at the same ionic strength in control incubations. Factor II 
concentrations were 0.1, 0.2, 0.5, and 0.75 U/ml. Velocity was
measured as the rate of thrombin formation which was proportional
2
=vot+l/2at .to the slope a/2 in the equation A 400
Fig. 2 Replot of slope of L-B plot (Fig. 1) vs choline concentration (15,
30, and 45 mM) to determine KT (15).I
Fig. 3 Replot of abscissa intercepts of L-B plot (Fig. 1) vs choline
concentration (15, 30, and 45 mM) to determine KT' (15).
Fig. 4 Dixon plot (1/v vs [I]). Factor II concentrations were 0.75 U/ml (O),
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